Sanofi/AstraZeneca Resolving Beyfortus Shortage By Reallocating Southern Hemisphere Supply

 
• By Sarah Karlin-Smith

With the White House putting a spotlight on US shortages of their new RSV monoclonal antibody, Sanofi and AstraZeneca can take some solace that the negative headlines stem from unexpectedly high demand and easier reimbursement for the immunization than the companies’ predicted.

infant in doctor's office with mask to help them breath
Sanofi and AstraZeneca say demand for their RSV immunization is unprecedented among similar launches. • Source: Shutterstock

More from Manufacturing

More from Compliance